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Stroke continues to be a significant cause of death and disability worldwide. Although
major advances have been made in the past decades in prevention, treatment, and rehabil-
itation, enormous challenges remain in the way of translating new therapeutic approaches
from bench to bedside. Thrombolysis, while routinely used for ischemic stroke, is only a
viable option within a narrow time window. Recently, progress in stem cell biology has
opened up avenues to therapeutic strategies aimed at supporting and replacing neural
cells in infarcted areas. Realistic experimental animal models are crucial to understand the
mechanisms of neuronal survival following ischemic brain injury and to develop therapeutic
interventions. Current studies on experimental stroke therapies evaluate the efficiency of
neuroprotective agents and cell-based approaches using primarily rodent models of perma-
nent or transient focal cerebral ischemia. In parallel, advancements in imaging techniques
permit better mapping of the spatial-temporal evolution of the lesioned cortex and its func-
tional responses. This review provides a condensed conceptual review of the state of the
art of this field, from models and magnetic resonance imaging techniques through to stem
cell therapies.
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INTRODUCTION
Stroke is the second cause of death worldwide (1). Thromboly-
sis with recombinant tissue plasminogen activator (rt-PA) reduces
mortality and morbidity from ischemic stroke, but is only avail-
able for around 5% of patients due to factors including neces-
sity of administration within 4.5 h of lesion onset (1–3). The
impact of new data proposing benefit for some patients of rt-
PA within 6 h remains to be defined (4). In recent years, several
avenues showing promises in pre-clinical research have failed
to reach clinical viability and the need for new therapeutics is
pressing (5).
Encouraging results have been accumulating in the domains of
stem cell therapy and growth factors (6, 7). These results should
be interpreted in light of systematic reviews identifying a lack of
consistent rigor in study design and over-representation of posi-
tive data in the pre-clinical animal and stem cell literature (8, 9).
However, investigational strategies can be enhanced through the
development of superior animal models of stroke and advances in
multi-modal magnetic resonance imaging (MRI), which offers a
non-invasive method of studying tissue microstructure, perfusion,
and functionality in vivo.
This review aims to provide a concise account of current
experimental approaches in ischemic stroke. The main animal
models will be recapitulated, before introducing recent advances
in experimental MRI, with a focus on diffusion-weighted imaging
(DWI), perfusion-weighted imaging (PWI), and functional MRI
(fMRI). Finally, emerging stem cell therapies are considered with
emphasis on explanation of relevant features for understanding
and designing translational research.
EXPERIMENTAL MODELS OF BRAIN ISCHEMIA
WHICH MODELS ARE AVAILABLE?
Human ischemic stroke usually results from middle cerebral artery
(MCA) occlusion, and so techniques which occlude this artery
are closest to the clinical picture (10, 11). Since open surgical
methods of MCA occlusion were first described in the 1970s
and refined in the 1980s (12–15), a number of additional tech-
niques have been proposed, some of which avoid craniotomy
(11, 16): the intra-luminal suture model (17–20) is commonly
used (identified by Howells et al. (20) as the method employed
in >40% of 2,582 neuroprotection experiments) but the throm-
boembolic model (21, 22), the coagulation or ligation model (17,
23), the endothelin-1 model (20–25), and the distal artery com-
pression model (26) provide alternatives. Here, a selection of
the principal models is introduced; for comprehensive details on
those of interest and other models, the reader is further referred
to recent in-depth reviews by Howells et al. and Krafft et al.
(20, 27).
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FIGURE 1 | (A) Vascular brain anatomy of the rat. Reproduced from
(10), by permission of American Heart Association Inc/Wolters
Kluwer Health. (B) Induction of middle cerebral artery occlusion
(MCAO) by insertion of thread into the external carotid artery
(Longa’s method, left) or common carotid artery (Koizumi’s method,
right). ACA, anterior carotid artery; AchA. anterior choroidal artery;
CCA, common carotid artery; ECA, external carotid artery; ICA,
internal carotid artery; HTA, hypothalamic artery; PPA,
pterygopalatine artery; PCOM, posterior communicating artery.
Reproduced from Ref. (23) by permission of Elsevier Inc.
Intra-luminal suture model
This model was developed in the rat by Koizumi in 1986, modi-
fied by Longa et al. (10, 28) (Figure 1) and later refined by Kamii
and Lo for application in mice (29, 30). A surgical filament intro-
duced via the internal carotid artery (ICA) reaches and occludes
the MCA at its origin (31). The technique may provide a model
of transient ischemia with reperfusion or permanent occlusion
according to whether the suture is left in place for 30 min to 2
or 24 h. Importantly, this technique does not require craniotomy
which introduces extra-lesional influences on intracranial pres-
sure and temperature (31). This relevance to clinical application
is accentuated since in human subjects, surgical decompression
post-stroke has been shown to extend survival through allevia-
tion of cerebral edema (20, 32). The intra-luminal suture model
is well-established in rat and mouse, but it is notable that lengthy,
careful practice remains necessary to avoid complications, such
as core temperature fluctuation, damage to neighboring struc-
tures, and hemorrhage, all of which can compromise experimental
accuracy (31).
One controversy regards the extent of tissue damage with this
model: there is evidence that, compared to the electrocoagulation
technique, this model induces a larger ischemic lesion that exceeds
the territory of the MCA to reach the thalamus, hippocampus,
and substantia nigra. This might be the result of an additional
effect on posterior carotid artery (PCA) flow, exerted by the intra-
luminal thread, as it ascends the ICA (17). Many aspects including
thread size and length, animal weight and strain, and exact fila-
ment positioning may contribute to vascular phenomena outside
the MCA in the intra-luminal model (18, 20). Similarly, a direct
comparison of the intra-luminal method or craniotomy plus MCA
ligation to perform MCA occlusion indicated that the surgical pre-
cision of ligation was able to achieve most stable infarct volume
and behavioral impairment (17). As the intra-luminal model is
susceptible to issues of anatomical accuracy of the induced dam-
age, a key consideration when implementing this model is the
reproducibility of infarct volume, which may vary between centers.
Despite these variables, the intra-luminal filament model is widely
considered adequate to reproduce primary ischemic insult and
subsequent neuronal cell death, glial activation, and blood brain
barrier (BBB) damage and skilled practitioners may achieve high
rates of experimental success (20, 33). Moreover, the presence of
a significant ischemic penumbra early after occlusion makes this
technique suitable for neuroprotection studies.
Thromboembolic models
These models may represent more closely the pathophysiology
of human ischemic stroke and offer potential to test throm-
bolytic agents (34), evaluate ischemic lesions after thromboly-
sis (35) and study combination therapies, such as thrombolytic
agents combined with neuroprotective drugs (27, 36). Early ver-
sions employed a human blood clot or suspension of homologous
small clot fragments (37). However, they induced infarcts wherever
spontaneous recanalization took place, and subsequent develop-
ment of a technique of embolization of an autologous clot came
closer to human arterial thrombi (38). This model remains widely
used in rats and mice (20). Some researchers have described a
model of embolic stroke employing microspheres which has been
stated to reduce variability in lesion development and represent
more closely the evolution over time and multifocal and heteroge-
nous nature of human disease,albeit with the limitation of forming
an irreversible insult (39, 40). However, a definitive microsphere
model remains to be defined, as recently Zhu et al. documented
at least one half of microspheres <100µm failed to lodge in the
rodent cerebral arterial circulation (41). This model is not suit-
able for reperfusion studies but avoids the complication of clot
autolysis in clot models.
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Excellent reproducibility is offered by the thromboembolic
stroke model, in which injection of purified thrombin to the
MCA can be performed with good precision (42). This model
was previously given poor consideration in neuroprotection stud-
ies after repeated failure in translating animal results to humans.
Moreover, the supra-physiological thrombin content in clots gen-
erated by this method may confer resistance to currently available
thrombolytic agents beyond what is evident in the clinical picture
(43). Yet despite perhaps greater accuracy of mechanical models,
these do not reflect hemodynamic characteristics of blood reper-
fusion or post-lesional cerebral metabolism, factors influencing
the response of brain tissue to neuroprotective agents (24).
Endothelin-1 model
This model achieves reversible occlusion of the MCA through
direct or nearby application of the potent vasoconstrictor
endothelin-1 (ET-1) (21, 22). It can be well reproduced in rats,
offering benefits of an absence of lesions at injection site and low
mortality, including in older animals, which is highly relevant to
the human epidemiology of stroke (44, 45). Other strengths are
its low invasiveness and its ability both to facilitate anatomical
targeting of the lesion and to be implemented in the absence of
anesthetic agents (20, 22, 23), some of which may attenuate stroke-
induced morbidity in small animal models through potentially
neuroprotective effects of hypothermia (20). It produces a dose-
dependent stroke intensity in direct application models (21), but
it is important to note a fourfold increase in dose requirement to
achieve infarct in anesthetized rats (46); moreover, the potential
for interaction of ET-1 with key molecular players in the patholog-
ical cascade or compounds under investigation must be considered
(20, 22). It is not effective as a sole agent in mice, in which species
it must be combined with another form of occlusion (23, 47).
Cerebral artery occlusion through electrocoagulation or
mechanical methods
This group of techniques requiring open surgical access includes
the electrocoagulation-surgical model described by Tamura and
colleagues in the early 1980s, since which time a number of
variations on this approach has been published (13, 48). While
experienced surgeons can attain excellent reliability and low mor-
tality with Tamura’s original method, disadvantages include the
high level of expertise necessary and the production of a fixed
deficit which inhibits study of thrombolytic therapies (20, 48).
Other mechanical methods of occlusion do permit the bene-
fit of reversibility, such as use of an adjustable surgical ligature
(49) or micro-aneurysm clips (50). These techniques also enable
the application of ischemia over a defined time period, although
both techniques – especially the use of clips – demand techni-
cal mastery, while to date creating a less predictable experimental
lesion than Tamura’s approach (48–50). A more recent alternative
is the transient distal middle cerebral artery occlusion (dMCAo),
devised by Morancho and colleagues in 2012 (26). This model
consists of compressing the distal portion of the MCA for 60 min
using a blunted needle, followed by 24 h of reperfusion. Even
though exposition of the left lateral skull and M1 portion of
the brain are required, in many aspects this model is less inva-
sive than the intra-luminal filament technique: certainly, vascular
structure is well preserved, though this is to the detriment of
inflammation induced by microglia even before the beginning of
the ischemia. The lesion volume and mortality are comparable
with the well-established permanent ischemia models, and this
model deserves further investigation to better characterize the
exact mechanisms of damage and recovery.
WHICH SPECIES?
Small animal models
According to the stem cell therapies as an emerging paradigm in
stroke (STEPS) guidelines (51, 52), an optimal pre-clinical stroke
model should reflect human epidemiology, incorporate thorough
monitoring of parameters of stroke development and collect
robust safety data. Compared to larger species, small animals are
less expensive, have easier husbandry and handling conditions, are
more suitable for ischemic surgery and genetic modification, and
are more ethically acceptable (23, 27). STEPS highlights the avail-
ability of proven rodent stroke models; in addition, the rat fulfils
a key STEPS requirement of reproducibility of results (23, 51, 52),
its cerebrovascular anatomy and physiology offers good similarity
to that of humans (11) and it is of practical size for physiological
monitoring and study of neuropathology via dissection or imaging
modalities (19, 23).
Nonetheless, much interest has arisen in murine models of
ischemic stroke, primarily focused on advances in genetic modifi-
cations permitting the modulation of specific molecular pathways
in transgenic animals (53–55). Of note, ischemic cell death accu-
mulates more rapidly in mice than rats, such that a 30 min MCAo
induces a lesion equivalent to that produced within 60–120 min
in rodents, while beyond this time the cerebral hemisphere is
quickly infarcted (56). Additionally, there may be considerable
inter- and intra-strain variability; for example, some transgenic
mice lack communicating arteries within the Circle of Willis,
notably the posterior communicating artery, which affects the
extent of ischemic damage resulting after experimental interven-
tion (57, 58). However, the challenge of differing cerebrovascular
organization may also be found in some strains of rat (20). Other
plausible factors are differences in arterial collaterals and sensi-
tivity to excitotoxic cell death (56). Post-infarct temperature is
a critical variable in both rats and mice; infarct onset may be
complicated by the onset of hypothermia, which is thought to
exert beneficial effect and is under debate as a clinical strategy (20,
56, 59), while hyperthermia exacerbates neurological deficits and
neuropathology in rats (60). Similarly, fever is reported to have a
deleterious influence over ischemia in a variety of clinical scenarios
(20, 59, 60).
Larger species
Successful models have been developed for a wide range of species,
including primates, pigs, dogs, cats, and rabbits. Larger animals
have better similarity to humans in terms of behavior and sen-
sorimotor integration, and STEPS and Stroke Therapy Academic
Industry Roundtable (STAIR) guidelines agree it is necessary to
test a positive result from a small animal drug study in a higher
species prior to clinical evaluation in humans (51, 52, 61). In par-
ticular, such studies are necessary for pharmaceutical evaluation,
including delivery and dosing of new compounds, which cannot
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be reliably derived from smaller animal models (51, 52, 61). In
many aspects, larger animals offer a closer model of human cere-
bral anatomy and organization, as represented by the ratio of
neocortex to basal ganglia and also the volume of white matter,
which is sparse in rodents but is more plentiful – nearer to human
neuroanatomy – in non-human primates (20, 27, 48). This is of
especial pertinence in the field of lacunar strokes since these lesions
most often occur in the deep white matter of human subjects
(27). In contrast to lissencephalic brains of mice and rats, those
large species which, like humans, have gyrencephalic brains, may
provide closer models of functional recovery (61, 62). However,
an important difference between the cerebrovascular organization
of humans and many larger species is that in the latter, anterior
blood supply to the brain is via a network of anastomosing ves-
sels (the carotid rete), and so experimental techniques in which
access to and occlusion of the MCA is achieved intravascularly
(e.g., intra-luminal suture) may rarely be implementable (20, 63).
In the late 1990s, a reproducible and controlled model of intrac-
erebral hemorrhage (ICH) was realized in the pig. As well as a low
cost, this animal is analogous to humans in a brain rich in gyri
and white matter (64). More recently, Imai et al. have proposed a
new model of focal cerebral ischemia in the miniature pig, thus
facilitating reproducible ischemic damage affecting gray and white
matter in a gyrencephalic brain of a smaller animal. Current limi-
tations include the potential influence of atmospheric exposure on
intracranial pressure, and impact of diathermy occlusion, which
may have the accessory effect of causing local blood–brain barrier
rupture, thus preventing the investigation of reperfusion (65).
Another new model is of canine embolic ischemic stroke,
which might have superior validity in terms of the exact rele-
vance to human pathophysiology. However, this model requires
more detailed characterization as well as confirmation by other
groups (66). In 2008, Boltze and colleagues developed a robust
model of focal cerebral ischemia in the sheep, with advantages of
some similarities within hematological values and blood groups
but fewer ethical dilemmas and lower mortality than primates.
For the authors, the major advantages of the sheep model lies
in its potential to study long-term impact of new therapeutic
approaches and safety and efficacy of autologous cell therapies,
to which the low cell yield of small species presents a practical
obstacle (67).
As well as the ethical and practical challenges delineated pre-
viously, the maturation time of larger species (12–18 months)
contributes financial factors to their place in drug development
studies, and indeed financial considerations have been proposed as
an impediment to the greater use of older animals, more reflective
of human epidemiology, in stroke studies (20). For experimental
ischemic studies, therefore, small animal and in particular rodent
models are currently and likely to remain the most appropriate
and widely used initial investigation platform (51, 52).
ROLE OF BEHAVIORAL AND FUNCTIONAL OUTCOMES
Structural outcome remains an imperfect predictor of progno-
sis including long-term recovery post-stroke (61). Studies in
humans have demonstrated a link between extent of tissue dam-
age and degree of functional impairment, and lesion volume
is proposed as part of clinical forecasting tools. However, it is
acknowledged that long-term resolution of neurological deficits is
not tied to lesion volume alone, with important influences includ-
ing age, gender, and co-morbidities (68). Additionally, there is
increasing recognition and understanding of the power of neu-
roplasticity in the repair of neurological deficits (69). Therefore,
together with methods which effect reproducible neuropathol-
ogy, behavioral, and functional measurements are an obligatory
component of animal models if the rate of translation of exper-
imental therapies to the clinic is to be improved (48, 51, 52, 61).
Moreover, these aspects assess what is in the real-life setting the
most meaningful impact to prospective patients of potential new
treatments (70).
Behavioral tests
A crucial issue in the translation from experimental to clinical
settings is endpoint choice: there are fundamental differences in
functional recovery measures adopted for humans and animals,
and these unavoidably contribute to the difficulty of replicating
experimental results in patients. Several comprehensive reviews
of behavioral tests are available (71–73). In brief, the relevant
domains are motor function, sensory function, and cognitive pro-
cessing; no “pure” test exists, and the various tests available probe
different combinations of multiple domains. It is therefore vital to
combine multiple assessments, performed in a highly controlled
manner.
The Rotarod remains one of the most widely used tests, involv-
ing positioning the rat or mouse on a rotating cylinder spinning
at varying rates. The time-to-fall is measured, and provides an
indication of general motor function and specifically motor learn-
ing. Notably, this test has been employed so widely that a key
advantage is the sheer number of studies available for comparison
of results. By contrast, the Wire Hanging test is a purer evalua-
tion of sensorimotor function: animals are trained to hang with
the forepaws to a metal thread, and the time-to-fall is measured.
Performance on this test is chiefly determined by sensorimotor
co-ordination. A less stressful and more ecologically comprehen-
sive test is the Adhesive Removal test, in which adhesive patches
are applied to the forepaws, and the time-to-removal is measured.
Typically, the adhesive on the unaffected hemisoma is removed
first, and the one on the other paw is removed significantly later,
due to weaker perception and motor performance difficulties. This
test includes more “general behavior” elements than the Rotarod
and Wire Hanging tests, and is performed in the animal’s cage.
Grip strength measurements, though common in other areas, are
seldom employed. On the other hand, very detailed data can be
acquired through computer-vision gait analysis systems, but such
systems may be prohibitively expensive (73–75).
Tests that tap more directly into general behavioral and cog-
nitive function include the Open field test and the Water maze.
The Open Field test involves positioning the animal in a large
open arena (50–100 cm) surrounded by suitable walls, and quan-
tify exploratory behavior based on landmarks such as squares or
with automated movement tracking; both horizontal and vertical
(standing) activity is quantified. The Water Maze test involves plac-
ing a rat or mouse in a pool,where an escape platform is hidden just
under the water surface; in presence of intact memory function,
the platform position is quickly learnt from environmental cues.
In presence of hippocampal damage, or sensorimotor impairment,
the escape trajectory becomes less direct (76–78).
Frontiers in Neurology | Stroke February 2014 | Volume 5 | Article 19 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Canazza et al. Experimental models of brain ischemia
From a neuroanatomical perspective, the tests above probe dif-
ferent combinations of cortical and subcortical integrity and as
such are complementary in respect to assessing functional impair-
ment and recovery after experimental ischemia. In addition, some
tests seem to be particularly suitable for the measurement of long-
term deficits, as they avoid “ceiling” effects due to rapid recovery of
baseline performance in the subacute phase; from this perspective,
tests that tap into general behavioral integrity, such as the Open
Field, Water Maze, and Adhesive removal tests appear to be more
sensitive than more elementary ones such as the Rotarod and Wire
Hanging tests (71, 73, 74, 77).
Functional recovery
Despite the many behavioral tests outlined above, an enduring
challenge is the lack of a standardized single battery of tests, which
might be used across the stroke research community for a partic-
ular animal model (48). Therefore, varying methods of functional
evaluation are employed by different research groups. The situ-
ation is more pronounced in mice than in rats, due to a more
established stroke research pedigree in the latter. Researchers are
addressing this scenario and a range of evaluations able to delineate
evolution of both short and longer-term neurological deficits in a
murine transient occlusion model of ischemic stroke was recently
announced (75).
Rodent and murine models have been developed which incor-
porate co-morbid factors such as old age and diabetes. Lindner
et al. studied functional deficits in 24-month-old rats in which
stroke had been induced using the intra-luminal suture method.
An initial problem was a very high post-procedure mortality rate
of 80% which, through utilization of a non-poly-l-lysine coated
suture, the group overcame to produce a much lower 24% loss (79).
Also using the intra-luminal suture model, Prakash et al. showed
diabetic rats demonstrated both inferior re-vascularization and
functional recovery to non-diabetic animals (80). One relevant
point for consideration when selecting measures of functional
outcome is that older animals may already exhibit baseline impair-
ment or even inability to perform certain assessments such as
beam-walking (79). It should also be considered that some tech-
niques of producing ischemia may intrinsically damage measures
of post-stroke recovery, for example, Tamura’s method which
affects muscles of mastication and hence feeding (70).
Functional recovery in rodents has also been studied in other
types of stroke induction, for example, the endothelin-1 and
embolic stroke models (81, 82). Whereas in the embolic model,
there was solid correlation of lesion size to functional neurological
outcome (81), an interesting difference was noted between hem-
orrhagic and ischemic lesions of equal size in the endothelin-1
animals. This was posited to reflect differing neuroplastic phenom-
ena in the different stroke etiologies, confirming that lesion size
alone is an imprecise predictor of eventual neurodisability (82). A
similar lack of correlation between lesion size and behavioral out-
comes has been detected in mice, leading to a conclusion that lesion
volume should not be considered in isolation, with functional
assessment an equally vital measure in pre-clinical studies (75).
There are a number of acknowledged difficulties in applying
results from small animal models to human subjects. Small species
are noted to mask functional impairments (48). They recover
more quickly than humans from neurological insult and har-
bor differences both in functional neuroanatomy, having a much
lesser degree of lateralization of brain function, and structural
neuronatomy, as outlined in Section “Larger Species” (48, 79).
On the other hand, primates more closely mirror both human
pathophysiology of stroke and mechanisms of neural repair in sev-
eral aspects including disease timeframe and cortical remapping
of a brain also adapted for lateralization of function (69, 83). In
addition, clinical manifestations of disease are rather similar; post-
MCA occlusion, marmoset monkeys demonstrate contra-lateral
weakness and neglect which parallels the deficits in human stroke
patients. Moreover, functional tests in primates can more closely
mimic and evaluate skilled motor tasks impacted in the human
condition (84). An additional factor is that the larger central
nervous system of primates facilitates imaging studies, although
recent murine research employed the technique of optical intrinsic
signaling which showed promise in the study of neuroplasticity in
this species (84, 85).
MAGNETIC RESONANCE IMAGING
Traditionally, the first-line approach to evaluate the characteristics
of stroke models and their response to therapeutic interventions
has been histopathological and immunohistochemical analysis.
While providing excellent structural detail and specificity, this
approach has the inherent limitation of not allowing longitudinal
examination, which is most important since the effects of thera-
peutic intervention on the spatial-temporal evolution of ischemic
lesions are complex and need to be assessed at multiple time points,
not just through an arbitrary “snapshot.” The need to track lesion
progression in time, both structurally and functionally, has thus
driven a shift from experimentation based on neuropathological
analysis to non-invasive in vivo imaging-based analysis (86).
At the center of an ischemic area it is often possible to identify
an irreversibly infarcted tissue core surrounded by a rim of acute
oligemia, where energy metabolism is largely preserved but at the
expense of severe tissue acidosis. This area, referred to as “ischemic
penumbra,” is less severely hypo-perfused than the ischemic core
and characterized by impaired neuronal activity without irre-
versible neuronal damage. Due to progressive metabolic failure
the penumbra unavoidably evolves to necrosis without therapeutic
intervention within a certain time window (87, 88). For this rea-
son, the early identification and recovery of penumbra represents
the principal aim of therapeutic strategies.
In the last 30 years, many imaging techniques have been pro-
posed to detect and distinguish penumbra from the ischemic
core. Positron emission tomography (PET) is still considered the
gold standard to delineate the penumbra, given that it provides
direct quantification of glucose metabolism integrity (89). Unfor-
tunately, the availability of PET is limited, particularly for experi-
ments on small animals that require dedicated micro-tomographs.
Until recently, the role of MRI has been limited to structural
imaging, particularly using T2-weighted sequences wherein very
good anatomical contrast is shown between healthy and infarcted
parenchyma. However, conventional structural MRI is hardly
viable as a longitudinal imaging tool, since the lesion-related con-
trast changes become visible only at the time when penumbra has
already largely converted to irreversible necrosis (90).
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In the last decade, novel MRI techniques known as DWI and
PWI have emerged, offering direct visualization of microstructural
damage and perfusional alterations and thus opening new win-
dows on the in vivo investigation of the pathophysiology of brain
infarction. In parallel, the use of fMRI in animal models has gained
ground, providing additional information on the integrity and
plastic re-organization of neural responses in peri-lesional and
contra-lateral areas (91).
DIFFUSION- AND PERFUSION-WEIGHTED IMAGING
Diffusion-weighted imaging reveals strong image contrast changes
within minutes following the onset of acute cerebral ischemia and
additionally allows the follow-up of tissue changes through the
subacute and chronic phases (92, 93). During ischemic stroke, the
apparent diffusion coefficient (ADC) follows a “U-shape” time-
course, characterized by a rapid initial decrease, as early as 20 min
after the onset of the ischemia (94, 95): intracellular water accumu-
lation, due to rapid failure of high-energy metabolism and associ-
ated ionic pumps, leads to cellular swelling (cytotoxic edema) and
consequent narrowing of the extracellular matrix volume (96).
This is a robust effect that is consistently observed in experimental
models (Figure 2) and patient studies. After 3–5 days, the ADC in
the irreversibly infarcted area begins to increase, due to cell lysis
and development of vasogenic edema; after a period of “pseudo-
normalization” of ADC values, the lesioned area stabilizes on high
diffusivity values. In particular, in acute phase ADC maps, when
combined with perfusion measurements, allow to distinguish the
core region from the penumbra, with ADC gradually decreased
from the periphery to the center of the ischemic region (97–99).
On the other hand, PWI provides information on the hemo-
dynamic status of brain tissue, delivering a multi-parametric rep-
resentation of regional perfusional state of regions with impaired
cerebral perfusion. In practice, PWI can be implemented using
an exogenous paramagnetic contrast agent or using endogenous
contrast through magnetic labeling of arterial blood. The first
approach is the most widely implemented one, is least demand-
ing in instrumental terms and provides very good measurement
accuracy (100, 101). However, it is hampered by the need to have
access to a suitably large vein to deliver a well-defined bolus. While
in rats the tail vein is frequently chosen, in mice it is very small and
collapses easily, so specific venous catheters are frequently utilized
to establish access to the femoral vein. PWI delivers multiple para-
meters representing perfusional status, notably cerebral blood flow
(CBF) and volume (CBV), time-to-peak (TTP), mean transit time
(MMT) (95, 100, 101). These are interpreted synergistically to
deliver a comprehensive picture of lesion status according to the
following temporal progression model. After onset of ischemia,
the ensuing vasodilator reaction first leads to an increase in CBV
and MTT, while successfully regulating the CBF to normal val-
ues. A further fall in arteriolar pressure leads to an additional
compensatory attempt, manifesting as a prolongation of MTT,
which however fails to regulate CBF that begins to decrease. As
the situation progresses toward local hemostasis, CBF falls drasti-
cally, the CBV paradoxically falls back to “normal” values and the
MTT is elongated even further; at this point, the supply of oxy-
gen and glucose is inadequate to support normal cell metabolism.
Eventually, the CBV and CBF fall to zero and the MTT becomes
un-measurable, at which point infarction has become irreversible.
In light of these relationships and of the associated temporal
progression, regions with a very low CBV can be taken as rep-
resentative of the infarcted core, whereas areas with near-normal
CBV and CBF but markedly increased MTT can be considered an
estimation of the extent of the ischemic penumbra (102).
The spatial extent of perfusional deficits consistently exceeds
the area of altered ADC, delineating a penumbral region where
hypoperfusion is present but not severe enough to cause irre-
versible metabolic failure with consequent cytotoxic edema. The
volumetric difference between these two areas, with near-normal
ADC values but reduced CBF, is called“DWI/PWI mismatch.” The
mismatch represents only a rough approximation to the real exten-
sion of penumbra, defined using the “gold standard” combination
of PET with anatomical examination. There are multiple reasons
why DWI and PWI can only approximate the penumbra extent,
most notably the fact that DWI is only a very indirect measure
of metabolic status, and the fact that there is no consensus on
the optimal thresholds to use to delineate abnormal diffusion and
perfusion. Further, thresholds optimized in one species or strain
may not be applicable in others (97, 98, 103). While considerable
FIGURE 2 | Diffusivity andT2 maps demonstrating the consequences of transient left MCAO in the rat. Time-courses of diffusion (ADC) and T2 contrast
changes. Early ADC pseudo-normalization is followed by a further reduction, until eventually the ADC is significantly elevated with respect to tissue in the
contralateral hemisphere and the two maps appear similar. Reproduced from Ref. (139) by permission of Wiley-Liss/John Wiley & Sons Inc.
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progress has been made in recent years, the choice of DWI and
PWI thresholds for penumbra delineation remains a severe issue
also in human clinical trials (101, 104). Nevertheless the DWI/PWI
mismatch is a convenient “surrogate” marker for the identification
of the ischemic penumbra, since it represents an often-acceptable
approximation to the real extent and does not require the use of
PET to study glucose metabolism (105).
Unfortunately, mainly due to scanning time limitations, many
research groups in the past have used only DWI or PWI alone for
assessing therapeutic response in experimental models. However,
those that do have obtained results clearly demonstrate the value of
combining these techniques. For instance, Jiang et al. have demon-
strated that rapid recanalization by means of rt-PA of embolically
occluded brain arteries leads to increased rCBF and ADC which
foreruns reduced lesion volume (106) (Figure 3). In another study,
Meng et al. using DWI/PWI mismatch in a MCAO model demon-
strated a reduction of volume of the infarcted lesion due to a
mechanical reperfusion at 60 min after ischemia onset (107).
FUNCTIONAL MRI
Rescuing the tissue in the ischemic penumbra is only one of the
possible approaches to mitigate the functional consequences of
brain stroke, and neuro-reparative therapies focus also on enhanc-
ing plasticity in the surrounding areas, and, more broadly, in
the trans-hemispheric neural circuits affected by destruction of
the lesioned cortex. It is therefore important to be able to study
how functional responses evolve in the progression from acute to
chronic phase. In clinical practice, fMRI has gained acceptance as
a tool to evaluate activation patterns in response to motor and
language tasks and, in stroke patients, the changes in activation
patterns that follow stroke onset and gradual functional recovery
have been explored in detail (108, 109).
In principle, fMRI has good potential for cross-translation
of functional results between patients and animals. However in
practice, its implementation in animal models is very challenging,
mainly because of the near-impossibility of implementing active
tasks that require effortful participation, limiting the usable par-
adigms to those based on passive stimulation. Despite obvious
differences, with respect to active tasks, somatosensory stimu-
lation paradigms have value because they do elicit significant
activity in pre-motor and motor cortices in addition to primary
somatosensory areas. Several studies have been published using
such paradigms in rats and mice, essentially demonstrating that
ischemic lesions in the sensorimotor cortex are associated to three
changes: (1) loss of hemodynamic response in the infarction core,
due to neural loss, and in the penumbra, due to metabolic dysfunc-
tion, (2) rapid emergence of increased contra-lateral activation,
principally representing loss of trans-callosal inhibition, and (3)
slow and gradual appearance of new ipsi-lateral activation clus-
ters in peri-lesional areas, representing re-organization attempts
to recuperate function through cortical plasticity (110–112).
The complexity of these response patterns implies that there is
no straightforward answer as to whether increased or decreased
activity in a given region is a sign of functional recovery. Some
studies have demonstrated that functional recovery is mainly asso-
ciated with activation patterns that resemble as closely as possible
those obtained prior to lesion onset (113) and that successful
reparative therapies enhance this pattern of functional recovery
(114) (Figure 4). For interpreting the nature of specific effects, cor-
relation with behavioral scores is essential, to distinguish between
loss of inhibition and functional specificity from genuine plas-
ticity supporting functional recovery (115, 116). There are two
main problems implementing fMRI in animal models. The first is
anesthesia, which by definition suppresses central nervous system
activity and for which there may be a very narrow dose mar-
gin available, implying that the dose cannot be lowered enough
to obtain reliable fMRI responses without also incurring into
movement artifacts. The other problem is that the hemodynamic
response at the basis of fMRI can be impaired for countless rea-
sons that are not related to neuronal function, such as impaired
cerebrovascular reactivity. For this reason fMRI is frequently per-
formed in conjunction with evoked potentials, which do not
FIGURE 3 |Temporal evolution of cerebral blood flow (CBF) changes for untreated (A) and recombinant tissue plasminogen activator (rt-PA)-treated
(B) rats after embolization. Reproduced from Ref. (106) by permission of Lippincott-Raven Publishers Inc/Nature Publishing Group.
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FIGURE 4 |Temporal changes of functional activation elicited by forepaw electrical stimulation over 6 months. Rats treated with stem cells (bottom)
demonstrated more rapid and marked “renormalization” of the activation pattern in comparison to controls (top). Reproduced from Ref. (114) by permission of
the authors.
provide good spatial information but, on the other hand, represent
neuroelectric activity directly and may therefore detect situations
where neural activity is preserved but rendered invisible to fMRI
through physiological confounds (116).
RESTING STATE FUNCTIONAL MRI
An alternative fMRI method, variously referred to as resting state
fMRI (rs-fMRI) or functional connectivity MRI (fcMRI), assesses
spatial functional correlations within neural networks without the
need of a stimulation paradigm. The notion is that of studying the
temporal coherencies that spontaneously emerge from intrinsic
brain activity and which remain manifest even under moderate
levels of anesthesia. This method has several potential practical
advantages, most notably that of not requiring active stimulation
with the associated equipment complexities and movement arti-
facts. Analysis of rs-fMRI datasets demonstrates the presence of
a rather well-defined set of stereotypical networks, which include
a “sensorimotor” network that spans the motor and sensor strips
bilaterally and extends to the pre-motor areas (117, 118). Recent
work has demonstrated that such networks are clearly identifiable
also in small animals and several groups are exploring the applica-
tion of these techniques to study functional re-organization after
stroke (119). Together with advanced network analysis, serial-
state rs-fMRI was used by Van Meer et al. to identify mutually
influential changes in gray matter functional connectivity, white
matter structural integrity and network topology of the sensory
and motor systems of both hemispheres and demonstrate impact
on functional gains in rats following medium or large single
hemispheric stroke (113).
CELL TRACKING
A further emerging application of MRI is the tracking of delivered
stem cells. Tracking the temporal progression of their diffusion
from the site of administration is obviously of central importance
for the development of reparative therapies, as much remains to
be understood about the guiding mechanisms and how migra-
tion to the lesion site can be promoted. Until recently, the role of
MRI was limited to tracking cells labeled with super-paramagnetic
compounds. While some studies have demonstrated successful
detection, substantial uncertainty remains regarding the ability
to unambiguously detect migrating cells over and above the exist-
ing anatomical contrast and, especially, about the inherent toxicity
that such compounds can have. A more recent approach is that
of labeling the cells with 19F, which is not physiologically present
and which can be detected with minimal modifications with MRI
hardware. This approach retains the advantages of MRI, in that
good anatomical contrast can be obtained through 1H imaging
and no radioactivity is involved, but has major advantages because
cell tracking signal is provided over an essentially zero physiologi-
cal baseline, and because the potential toxicity issues encountered
when embedding large doses of metallic compounds in stem cells
are inherently avoided (120–123).
While there is a wealth of literature on MRI-based cell track-
ing for monitoring reparative interventions in neurovascular and
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oncological disease, there are fundamental issues that remain
open and need careful consideration (124, 125). Although exist-
ing studies demonstrate that short-term tagging under experi-
mental conditions is feasible, we still have a rather constrained
understanding of the effect of tagging on biological viability,
of the exact bio-kinetics of the tagging molecules and of long-
term tagging stability. For example, a very recent study has
demonstrated that iron oxide nanoparticles administered intra-
venously after MCAO, which can produce intense signal changes
in the ischemic region, are not phagocytosed by blood-borne
leukocytes and do not enter the ischemic mouse brain as pre-
viously believed (126). The authors highlight the issue as an
example of publication bias in a controversial area, involving
a potential “decoupling” between the beliefs of the majority of
researchers, who are aware that certain tagging techniques have
certain limitations, and the published literature, where positive
findings are preferentially highlighted in the most influential
journals.
Other issues that remain to be addressed carefully include that
of false positivity due to label retention by dead cells and label
uptake by “bystander” cells; further, while binary detection can be
attainable, reliable quantification is extremely complex, because
the relationship between cell density and signal changes can be
highly non-linear, due to tracer dilution as well as to a range
of endogenous contrast sources which can confound measure-
ments, such as iron content in the basal ganglia and bone marrow
(BM) (127). While short-term tagging can be highly informa-
tive in experimental conditions, translational applications will
unavoidably rely heavily on long-term longitudinal assessments,
the feasibility and reliability of which critically depends on long-
term toxicity, stability, and retention, as well as on stability of
intrinsic tissue contrast, all of which have been investigated only
partially and may require recourse to large animal models to obtain
a more definite characterization (128).
Future work will, in particular, need to assess comparatively
the strength and weaknesses in terms of toxicity and stability of
magnetic microparticles and fluorinated compounds; the biophys-
ical differences are profound, and this reflects on the suitability of
different marking strategies in experimental or translational appli-
cations (123). Notably, while MRI-based cell tracking can have a
wealth of advantages in terms of availability of multiple anatomi-
cal and functional contrasts and ease of clinical translation, PET-
and optical imaging-based cell tracking is feasible and can have
substantial sensitivity advantages (129).
CELL-BASED THERAPEUTICS
THE NEED FOR NEW STRATEGIES
Thrombolysis with rt-PA is the standard intervention in ischemic
patients. Although this reduces disability if administered accord-
ing to protocols, it carries a risk of ICH of 5.2%, as compared
to 1% in controls (3). Moreover, many patients arrive outside of
the therapeutic window and the time of onset of the ischemic
insult may be unknown (1). Therefore new interventions are desir-
able to halt the ischemic damage and preserve undamaged brain
regions. Since neuroprotective compounds showing promise in
animal studies have yet to demonstrate efficacy in clinical tri-
als (5) encouraging data from animal studies of stem cell-based
therapy represents a valuable investigative avenue (53). Stem cell
transplantation could be implemented weeks or months after
injury, extending opportunities for therapeutic intervention (7,
130, 131). Indeed, there are positive expectations of human tri-
als currently underway to explore stem cell administration in the
long-term neuro-rehabilitation phase (130).
TYPES OF STEM CELL THERAPY
Different routes for the potential acquisition of stem cells exist;
they may be obtained endogenously through mobilization of the
patient’s own neural stem cells (NSCs), or exogenously in the form
of a multipotent cell type, mesenchymal stem cells (MSCs) (1,
132). Exogenous sources of MSCs include embryonic material,
certain adult tissues, e.g., BM (which also offers the opportunity
of autologous grafting) and adipose tissue (133–135). One advan-
tage is that MSCs do not express the major histocompatibility
complex in their undifferentiated state, therefore the risk of tissue
rejection at the time of implantation remains low. Therapy could
be achieved through transplantation to the affected region of cells
pre-differentiated in vitro (136), or through direct injection of
stem cells differentiating in vivo into the needed cell type (137).
There is evidence that stem cells migrate preferentially to injured
areas and release factors promoting survival and regeneration in
areas of high resident cell death (138). This may be the key mech-
anism by which such cells promote recovery, as suggested by a
model of rodent ischemia, where transplanted murine NSCs were
no longer viable at 6 months and could not create connections
within existing brain tissue (114).
ENDOGENOUS NSCs
In 2002, two research groups observed transient MCAo in the
rat inducing expansion of neuroblasts from the ipsi-lateral sub-
ventricular zone (SVZ); unexpectedly, these cells migrated in
chains to the ischemic penumbra (140, 141) rather than their
customary destination, the olfactory bulb. Some survived and dis-
played markers of mature striatal spiny neurons akin to those
destroyed by the infarction, with new neurons added to the stria-
tum for months (142, 143) or even a year (144) after stroke. There
is a growing list of endogenous molecules involved in the regula-
tion of adult neurogenesis, such as bFGF (basic Fibroblast Growth
Factor), which promotes cortical cell replacement and functional
recovery in neonatal (145) and adult (142) rats; EGF (Epidermal
Growth Factor), a more potent augmenter of SVZ-derived cells
in striatal tissue (146); and Nogo-A, a neurite inhibitor influen-
tial in murine models of ischemia and whose signaling cascade
wields critical input in the regulation, maturation, and migration
of NSCs from the SVZ (147, 148). However, debate continues
over long-term functional improvement; in a murine model of
stroke, animals in which blockade of endogenous neural stem
cell production was inflicted suffered larger stroke volume and
short-term worsening of performance on a number of behav-
ioral measures, but at 12 weeks there was no difference in deficits
between treatment and control groups (149). Investigation of fac-
tors in mobilizing NSCs should devote similar attention to their
potential for unexpected adverse effects. Excessive stem cell pro-
liferation is a well-known risk factor for genetic mutations and
malignant transformation, and endogenous NSC mobilization is a
young technology compared to use of MSCs, whose study stretches
decades (150, 151).
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EXOGENOUS DELIVERY
General considerations
Advantages of exogenous stem cell transplantation include control
over cell delivery, reducing risk associated with mitogen infusion,
and cell fate control (152). An additional quality is the potential to
genetically modify MSCs by means of a plasmid vector to express
beneficial proteins. For example, erythropoietin-expressing BM-
derived MSCs have successfully been introduced in a murine
model of anemia, remaining biologically active for up to 5 weeks
and providing an alternative to viral vectors, which may be asso-
ciated with some safety concerns as well as challenges in devising
a successful vehicle for delivery (153).
Technical considerations include whether administration
should be via the vasculature (154) or directly into the brain (155).
For example, BM-derived stem cells are more frequently delivered
intravenously, whereas NSCs are injected directly into the brain
parenchyma. In animal models of cerebral ischemia, improved cell
survival and neuroprotection is seen with delivery to the penum-
bra compared to the ischemic core (156). Dharmasaroja reviewed
three methods of MSC transplantation and differentiation: intras-
triatal, intracarotid, and intravenous (IV), concluding capability
of cells to reach the pathological site and positive effects by all
three routes (133). Although intracerebral delivery of MSCs may
additionally reduce lesion size, IV infusion also offers biological
and functional benefits and may be more practical in a clinical
setting (133) albeit permitting fewer cells to reach the central ner-
vous system than more direct routes (132). IV administration
seems to be the optimal route for chronic stroke treatment, as
shown in small clinical studies where no major adverse effects were
found (157). Nevertheless, intra-arterial (IA) delivery has shown
higher cell engraftment in the brain compared to IV administra-
tion, but it requires further development since it produces new
brain infarction in animal model studies (158).
MSCs from embryonic and adult niches
Drawing on evidence that BM cells may develop into a variety of
neural cell lines (159, 160), Zhang and colleagues (161) injected
BM mononuclear cells from healthy adult mice into the tail vein of
mice with MCA coagulation. Cells attained the peri-infarct zone
and transdifferentiated into putative cortical neurons within the
first few weeks of post-experimental injury, adding to evidence
for beneficial effects of BM cells in the treatment of experimental
acute brain injury (161–165).
Wakabayashi et al. reported that IV transplantation of MSCs
from the marrow of human fetal vertebrae significantly improved
the neurological condition of rats 7 days after MCAo, which is
suggestive of biological pathways outside of differentiation into
neuronal cells and CNS integration (164). MSCs were undiffer-
entiated in the ischemic core at 3 days and almost undetectable at
seven, but they fostered reduction of infarct volume and functional
recovery through graft-induced modulation of neurotrophic fac-
tors and beneficial cytokines in host cells. This is not the only
paper demonstrating that transplanted MSCs remain undiffer-
entiated. Tsai et al. noted a similar phenomenon, but although
few MSCs differentiated to neural cell types they exerted a favor-
able effect on angiogenesis, probably through mediating release of
neurotrophic factors by host cells. Of potential clinical relevance,
pre-treatment with established mood stabilizers lithium and val-
proate had increased numbers of MSCs homing to the ischemic
destination (165).
Functional benefits of stem cell therapies have been demon-
strated in rodent MCAo models. In one study, IV delivery of MSCs
from rodent BM achieved improvement in neurobehavioral out-
comes of treated compared to control rats at 12 weeks, although
few cells attained the central nervous system. These results were
credited to positive changes in both the peripheral and central ner-
vous system immunological milieu (166). Another study employed
human umbilical cord blood-derived MSCs, given intrathecally or
intravenously in a rodent MCAo model of stroke (167). Although
functional progress was similar in both groups, more effective
cell migration and neural differentiation and a greater impact
on ischemic damage was observed with the intrathecal route. A
barrier to clinical application in humans is the large number of
cells required in both methods. Despite this, in light of their posi-
tive potential, further study of BM-derived MSCs is warranted to
delineate their use in more detail, including long-term functional
benefits, especially as autologously derived cells are relatively avail-
able and do not carry the ethical and immunological drawbacks
of fetal material (133, 154).
Differentiation of human adipose cells
An alternative and plentiful source of adult MSCs is adipose tissue,
which is accessible with a potential supply via liposuction proce-
dures (134, 135). It poses fewer ethical challenges than embryonic
sources and adipose-derived stem cells (ASC) may have greater
potency in regenerative settings than other cell types. A murine
study of ischemic stroke therapy highlighted a 1000-fold richer
density of MSCs in adipose tissue compared to BM, and ASCs are
known to expand more efficiently than BM stem cells of equiv-
alent density and proliferation index (9, 168, 169). Ikegame and
colleagues (168) found that after 48 h in culture, ASCs secreted
higher levels of growth factors including hepatocyte growth fac-
tor (HGF) than BMSCs. In vivo experiments supported this ASC
potential, demonstrating both improved functional performance
and higher quantities of growth factors and smaller lesion size
on neuropathological samples of ASC compared to BMSC-treated
mice (Figure 5). As in other studies, the transplanted cells did not
thrive as none were detected in histological analysis of the infarct
at 24 h, again suggesting gains are due to trophic influences and
even that transplanted cells may not differentiate conclusively into
mature neural lineages (168, 169). In addition to positive experi-
mental effects, since ASCs offer options of autologous harvesting
and bear low potential for immunological reactions, their inves-
tigation as stroke therapy should certainly continue. However,
long-term safety studies are vital before clinical implementation,
as secretion of trophic factors and indeed tumorigenicity of MSCs
may create risk of neoplasm (170).
EVALUATING THE LITERATURE
Despite the promise and excitement of stem cell based thera-
pies, the high risk of publication bias must be acknowledged,
since it has been estimated as high a number as 1/6 of animal
stroke studies are not reported. Moreover, not all pre-clinical stud-
ies employ robust experimental methods such as randomization
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FIGURE 5 | Representative tetrazolium chloride strained sections of
ischemic mice treated with vehicle (left panel), adipose stem cells
(ASC, central panel) and bone marrow stem cells (BMSC, right panel).
Reproduced from Ref. (168) by permission of Informa Healthcare Inc.
and blinding to outcome, nor do they enroll animals reflective
of human epidemiology – namely elderly patients with underly-
ing health problems (8, 9). Lees et al. specified stringent inclusion
criteria for a systematic review and meta-analysis of autologous
and allogeneic (but not endogenous) animal stem cell studies in
ischemic stroke, and concluded pre-treated allogeneic cells admin-
istered concurrently with immunosuppression or anesthesia were
superior in aiding functional recovery, although autologous cells
were found to offer greater benefit for structural repair. Inter-
estingly, neither dosing nor timing of intervention was assessed
as critical to functional improvement (9). These findings illus-
trate how addressing consistency and quality of pre-clinical trials
is necessary for selection of appropriate study design, therapeu-
tic approaches and treatments to carry forward for assessment in
human populations.
CONCLUSION
Investigators seeking to select a suitable animal model of stroke
should consider their research hypothesis as different models are
appropriate according to whether, e.g., ischemic insult or reper-
fusion injury is the focus. Rodent models are recommended by
international authorities and combine similarity of cerebrovas-
cular anatomy to humans with a practical handling size, but
genetic manipulation studies are most suitably achieved in mice
(51, 61, 152). Particularly due to ethical considerations, judicious
use of larger animal models is indicated, and in this regard the
recent development of a sheep model, which is rarely a com-
panion species, may offer promise (65). The emerging imaging
techniques facilitate combination of non-invasive, high-resolution
anatomical analysis with detailed, multi-parametric physiological
mapping. Perfusion MRI alone can provide detailed information
about the evolution of ischemic lesions, confirming the validity
of models and the effect of possible revascularization interven-
tions. Perfusion and diffusion MRI taken together deliver a good
approximation of the ischemic penumbra, and therefore enable
experiments to directly assess recovery of at-risk tissue in sub-
chronical time-windows. In parallel, fMRI enables assessment
of how reparative interventions can modulate the physiological
re-organization processes that take place in the peri-lesional cor-
tex, and at system-level. The currently available models and MR
imaging techniques thus provide a robust platform for investigat-
ing possible reparative interventions. Despite much attention in
past decades on stem cell therapy, human application remains in
its early stages and benefits, particularly with exogenous thera-
pies, are likely due to a positive bystander effect rather than the
generation of functionally relevant synapses (171). Endogenous
therapy is therefore a key research goal, but is less advanced than
exogenous strategies. Of these, while ASCs may be more readily
extracted, a greater body of evidence exists for BM-derived stem
cells (172). However, any approach should consider safety issues
and the hypoxic and pro-inflammatory nature of the target tissue
with MSC priming and concurrent neuroprotective therapy likely
prerequisites of treatment (130, 133, 165, 172).
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